MAPT and Alzheimer disease: These results further support the hypothesis that BDNF Val66Met moderates the effects of Aβ on AD clinical disease progression via its effect on tau (Lim, et al., 2018; Lim, et al., 2022) by showing this effect on tau in the sporadic form of AD.